Clinical Trials Logo

Recurrent Basal Cell Carcinoma clinical trials

View clinical trials related to Recurrent Basal Cell Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04155190 Terminated - Clinical trials for Recurrent Basal Cell Carcinoma

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Start date: December 20, 2019
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with non-Gorlin HF-BCC (high-frequency basal cell carcinoma). Participants will be randomized (1:1) to receive either Patidegib Topical Gel, 2%, or Vehicle for 9 months. Randomization will be stratified by gender. The primary endpoint is the number of nSEB (surgically eligible basal cell carcinoma) that develop on the face over the 9 month period. The primary end point will be assessed by imaging and tracking of BCCs consistently throughout the study in order to identify nSEBs.